Literature DB >> 33516177

Occlusive retinal vasculopathy with macular branch retinal artery occlusion as a leading sign of atypical hemolytic uremic syndrome - a case report.

David Pérez González1, Matias Iglicki2, Shuli Svetitsky3, Yaeli Bar-On4,5, Zohar Habot-Wilner4, Dinah Zur1,4.   

Abstract

BACKGROUND: Hemolytic Uremic Syndrome (HUS) is a rare disorder characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure, considered within the group of thrombocytic microangiopathies. Ocular complications in HUS are very rare. Here, we report an adult patient who suffered from acute onset of paracentral scotoma, caused by branch retinal artery occlusion (BRAO), as a leading symptom of atypical HUS. CASE
PRESENTATION: A 39-year-old healthy male was lately diagnosed with essential hypertension and mild renal impairment. He complained about acute onset of central scotoma in his left eye. Fundus examination revealed marked narrowing of retinal vessels, cotton wool spots and few retinal hemorrhages in both eyes. The patient was diagnosed with bilateral ischemic retinal vasculopathy and acute macular BRAO in his left eye. Workup revealed thrombocytopenia, worsening renal failure. Renal biopsy showed signs of chronic thrombotic microangiopathy. The patient was diagnosed with atypical HUS (aHUS) and started on plasmapheresis, together with eculizumab. As his condition continued to worsen, he was put on renal replacement therapy. Due to a persistent monoclone of IgG1, the patient underwent bone marrow biopsy which revealed Monoclonal Gammopathy of renal significance, triggering a HUS and treatment was initiated accordingly. Two months after initial presentation, the patient developed neovascularization of the optic disc (NVD) in his left eye, and was treated with 3 monthly intravitreal bevacizumab injections with complete regression of the NVD. The patient suffered from myocardial infarction in the later course and was lost for follow-up. He returned 11 months after the last bevacizumab injection because of sudden loss of vision in his left eye caused by a dense vitreous hemorrhage. Biomicroscopy revealed a new NVD in his right eye. The patient underwent panretinal photocoagulation in both eyes with regression of neovascularization. Vision improved and remained 20/20 in both eyes.
CONCLUSION: We present a case report showing retinal ischemia can be linked with aHUS. As clinal diagnosis might be challenging, physicians should be aware of the rare ocular manifestations of this devastating multi-organ disease. In case of retinal ischemia, panretinal photocoagulation should be initiated soon to avoid blinding complications.

Entities:  

Keywords:  Atypical hemolytic uremic syndrome; Case report; Occlusive retinal vasculopathy; Paracentral acute middle Maculopathy

Mesh:

Year:  2021        PMID: 33516177      PMCID: PMC7847162          DOI: 10.1186/s12886-021-01820-x

Source DB:  PubMed          Journal:  BMC Ophthalmol        ISSN: 1471-2415            Impact factor:   2.209


  19 in total

1.  MONOMER--DIMER FORMS OF BENCE JONES PROTEINS.

Authors:  G M BERNIER; F W PUTNAM
Journal:  Nature       Date:  1963-10-19       Impact factor: 49.962

2.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

Review 3.  Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management.

Authors:  Meera Sridharan; Ronald S Go; Maria A V Willrich
Journal:  J Immunol Methods       Date:  2018-07-19       Impact factor: 2.303

Review 4.  Cardiovascular complications in atypical haemolytic uraemic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2014-01-14       Impact factor: 28.314

Review 5.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Authors:  Phillip I Tarr; Carrie A Gordon; Wayne L Chandler
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

Review 6.  Pathogenesis and treatment of maculopathy associated with cavitary optic disc anomalies.

Authors:  Nieraj Jain; Mark W Johnson
Journal:  Am J Ophthalmol       Date:  2014-06-14       Impact factor: 5.258

7.  Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom.

Authors:  C Mark Taylor; Sam Machin; Stephen J Wigmore; Tim H J Goodship
Journal:  Br J Haematol       Date:  2009-10-11       Impact factor: 6.998

8.  Optic coherence tomography angiography follow-up in a case of Purtscher-like retinopathy due to atypical hemolytic uremic syndrome.

Authors:  Juan Francisco Santamaría Álvarez; Anna Serret Camps; Javier Aguayo Alvarez; Olga García García
Journal:  Eur J Ophthalmol       Date:  2019-03-06       Impact factor: 2.597

9.  Hypertensive choroidopathy in atypical hemolytic-uremic syndrome.

Authors:  Maria Sole Polito; Federica Machetta; Antonio M Fea; Chiara M Eandi
Journal:  Eur J Ophthalmol       Date:  2019-12-25       Impact factor: 2.597

Review 10.  Atypical hemolytic uremic syndrome.

Authors:  Chantal Loirat; Véronique Frémeaux-Bacchi
Journal:  Orphanet J Rare Dis       Date:  2011-09-08       Impact factor: 4.123

View more
  2 in total

1.  Unusual eye findings in a patient with atypical hemolytic uremic syndrome: Answers.

Authors:  Begüm Avcı; Şengül Özdek; İmren Akkoyun; Esra Baskın
Journal:  Pediatr Nephrol       Date:  2022-01-27       Impact factor: 3.651

2.  Transient vision loss associated with paracentral acute middle maculopathy detected on multi-modal imaging.

Authors:  Jesse D Sengillo; Lily Zhang; Jayanth Sridhar; Harry W Flynn; Stephen G Schwartz
Journal:  Am J Ophthalmol Case Rep       Date:  2021-08-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.